NCT06918132View on ClinicalTrials.gov

Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 29, 2025

Primary Completion Date

April 29, 2027

Study Completion Date

April 29, 2027

Conditions
Lung Non-Small Cell CarcinomaStage IB Lung Cancer AJCC v8Stage II Lung Cancer AJCC v8Stage III Lung Cancer AJCC v8Stage IIIA Lung Cancer AJCC v8Stage IIIB Lung Cancer AJCC v8
Interventions
PROCEDURE

Biospecimen Collection

Undergo tissue and blood sample collection

BIOLOGICAL

Cemiplimab

Given IV

BIOLOGICAL

Fianlimab

Given IV

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

PROCEDURE

Surgical Procedure

Undergo SOC surgery

Trial Locations (1)

55905

RECRUITING

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT06918132 - Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter